Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Psychiatric disorders during pregnancy.

A D Cott1, K L Wisner

  • 1Department of Psychiatry, Johns Hopkins University, Baltimore, Maryland 21287, USA. acott@jhmi.edu

International Review of Psychiatry (Abingdon, England)
|July 28, 2004
PubMed
Summary

Managing psychiatric disorders in pregnant women requires careful risk-benefit analysis of treatments. Emerging evidence suggests many psychotropic medications pose low risks, facilitating informed patient discussions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pilot validation of blood-based biomarkers during pregnancy and postpartum in women with prior or current depression.

Translational psychiatry·2021
Same author

The impact of education, country, race and ethnicity on the self-report of postpartum depression using the Edinburgh Postnatal Depression Scale.

Psychological medicine·2016
Same author

Rationale and design for an investigation to optimize selective serotonin reuptake inhibitor treatment for pregnant women with depression.

Clinical pharmacology and therapeutics·2016
Same author

Pharmacologic evidence to support clinical decision making for peripartum methadone treatment.

Psychopharmacology·2012
Same author

Pharmacotherapy for depressed pregnant women: overcoming obstacles to gathering essential data.

Clinical pharmacology and therapeutics·2009
Same author

Randomized dose-ranging pilot trial of omega-3 fatty acids for postpartum depression.

Acta psychiatrica Scandinavica·2006

Area of Science:

  • Psychiatry
  • Obstetrics
  • Pharmacology

Background:

  • Pregnancy presents unique challenges for managing psychiatric disorders.
  • Maternal illness and psychiatric medications can pose risks to the fetus.
  • Effective communication regarding treatment options is crucial for optimal care.

Purpose of the Study:

  • To highlight the importance of risk-benefit discussions in treating pregnant women with psychiatric disorders.
  • To address the need for better research in psychopharmacological treatments during pregnancy.
  • To encourage open communication between clinicians and patients regarding treatment options.

Main Methods:

  • Review of current literature on psychotropic medication risks during pregnancy.
  • Analysis of the balance between psychiatric symptoms and treatment side effects.
  • Emphasis on the importance of physician-patient communication.

Main Results:

  • Emerging evidence indicates low risk associated with many psychotropic medications in pregnancy.
  • A lack of comprehensive research has historically been a barrier to informed decision-making.
  • Uncertainty should not impede necessary risk-benefit dialogues.

Conclusions:

  • Psychiatrists should stay updated on the latest research regarding psychotropic medication safety in pregnancy.
  • Open and frank discussions about risks and benefits are essential for pregnant patients with psychiatric conditions.
  • Evidence suggests that many psychotropic medications can be used with low risk during pregnancy, supporting informed treatment choices.

Related Experiment Videos